Q-omics provides the consensus-scored ZBTB14 profile across patient tissues and cancer cell-line models. ZBTB14 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZBTB14 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, ZBTB14 protein abundance shows 22,844 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KICH, and GBM as cancer lineages where ZBTB14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB14 survival associations across molecular data types. ZBTB14 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB14 RNA expression–survival associations across cancer types. High ZBTB14 expression shows unfavorable associations in ACC and SCLC, but favorable associations in KIRC, BRCA, SKCM and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZBTB14 RNA expression.
This table summarizes ZBTB14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ZBTB14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB14 shows lower tumor expression in KICH and THCA and higher tumor expression in KIRC, LIHC, HNSC and CHOL. The KICH box plot shows higher ZBTB14 RNA expression in normal versus tumor tissue (log2 FC = −1.261, t-test p < 0.001).
This table shows molecular features associated with ZBTB14 in patient tissues and cancer cell lines. In patient samples, ZBTB14 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZBTB14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
